These data clearly show that increased NAD+ levels at the end of the activity period are less efficient in synchronizing mTOR signaling pathway than high NAD+ at the onset of activity, and reinforce the notion of a chronotherapeutic approach as the best therapy for the treatment of metabolic diseases by NAD+ boosters. This evidence concerns the gene MTOR and metabolic disease.